Plastic Surgery Research Council
Members Only  |  Contact  | 
Primary Lab Contact
Name Benjamin Levi
Title Director Laboratory, Assistant Professor in Surgery
Phone 847-571-6511
Email blevi@umich.edu

Website http://burnwoundlab.com
Laboratory Burn/Wound and Regenerative Medicine Laboratory
Lab Location 1150 W. Medical Center Drive 3328 Medical Science Building 1 - SPC 5677
Ann Arbor, MI 48109
Lab Category Tissue Engineering
Wound Healing
Other: Stem Cell and Bone Biology
General Lab Setup Our laboratory is located on the University of Michigan Medical Campus. Our laboratory is comprised of a diverse group of scientist, technicians, and trainees. Members of our laboratory have backgrounds ranging from bone biology, biomedical engineering, immunology, and medicine . We currently are comprised of a senior staff scientist, two junior faculty scientist, one post doctoral fellow, medical residents and students, a laboratory manger, and two support technicians.
Lab Facilities Our laboratory is outfitted to facilitate experiments and research which involve animal models, tissue culture, histology and molecular biology. In addition to the resources within our laboratory we collaborate extensively with investigators across campus, particularly in the Cell and Molecular Biology Program, Orthopedic Surgery, Radiology, Developmental Biology and Bioengineering. We also have access to multiple cores across campus such as the Vector/Gene Therapy Core, Transgenic Animal Core, DNA sequencing Core, Microscopy Core, Flow Cytometry Core, Imaging Core, and Morphomics Core.
Animal Facility Yes (Mouse, Rat and Pig)
Type of Research 1. Heterotopic Ossification: Early diagnosis and Prevention strategies As many as 65% of our severely combat-injured service members will go on to develop heterotopic ossification (HO), a musculoskeletal disorder characterized by the formation of mature bone in soft tissues including muscle, tendon, ligaments and fascia. As a complication of trauma, HO presents the most important barrier to functional recovery and independence. Furthermore, over 60% of civilian major burn patients and over 50% of joint replacement surgery patients develop HO, with risks that only increase after subsequent operations. The pervasive nature of HO extending across several tissue types suggests that treatment directed to a specific tissue may be ineffective, whereas therapy directed towards centrally acting pathways may be more effective. Once bone forms around a joint, patients develop debilitating joint contractures and loss of mobility. Surgical excision of HO can be attempted to restore function, but patients with periarticular HO rarely regain complete range of motion, with contractures due to persistent or recurring HO. Current medical strategies to prevent de novo or recurrent HO including glucocorticoids, bisphosphonates, and non-steroidal anti-inflammatory medications either have significant side effects and/or uncertain impact, possibly because they fail to target key pathways involved in HO formation. In addition to effective therapies, methods of identifying potential HO patients prior to radiographic diagnosis are needed to target early intervention to a population that is likely to benefit. Given the burden of HO disease in these populations, its high morbidity and suboptimal treatments, there is substantial need for early diagnosis and therapy to inhibit HO by targeting its causative processes. The goal of this research is to change the treatment paradigm of HO from delayed diagnosis and resection to early detection and prevention. 2. Bone Tissue Engineering Alloplastic bone substitutes are prone to infection and inflammation, while autogenous bone grafts are limited in availability and create a donor-site defect. Thus, there is a significant need for readily available autogenous tissue which can aid in bone regeneration without resulting in a donor-site defect. The purpose of this study is to demonstrate the role of ALK2, a BMP type I receptor, as a novel target to 1) improve in vitro mesenchymal stem cell osteogenic differentiation and 2) enhance in vivo bone regeneration and calvarial healing. 3. Allograft Survival Cadaveric allotransplantation offers a promising option for reconstruction in patients with extremity burns and mutilating trauma. However, rejection of transplanted tissues (e.g. skin, hand, or arm) presents a significant clinical barrier to allograft survival. Lymph nodes are a known site of alloantigen presentation, an important step in the development of rejection. The extremities are particularly amenable to interventions involving lymph nodes due to their consistent lymphatic drainage patterns. The goal of the proposed project is to target the sentinel lymph node basin as a method to delay or completely mitigate the immune rejection of an extremity allograft. We will also characterize additional surgical and therapeutic measures which may further modulate this response. 4. Stem Cell and Developmental Biology. In addition to trying to better understand the key pathways involved in ectopic bone formation and bone healing, we are also working to isolate the progenitor cells responsible for these processes. 5. Muscle Fibrosis-Ischemia reperfusion model-Specifically, we are interested in investigating the thrombi and neutrophil extracellular trap formation in the femoral artery and microvasculature following injury.
1. Investigator's Name Levi Laboratory Members

Grants NIH K08, NIH RO1, DOD, American College of Surgeons
Opportunity for Student Degree Program Yes  
Research Fellowship Available Yes
Funding Available For research supplies and experiments
Educational or Prior Experience Requirements MD or PhD